Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Lakewood-Amedex Biotherapeutics Inc. (LABT) had Return on Tangible Equity of 32.49% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
-1.42M |
|
-- |
|
-- |
|
0.89M |
|
-0.89M |
|
-0.04M |
|
-0.92M |
|
-0.92M |
|
-0.92M |
|
-0.92M |
|
-0.92M |
|
-0.92M |
|
-0.89M |
|
-0.86M |
|
0.70M |
|
0.70M |
|
-2.00 |
|
-2.00 |
|
| Balance Sheet Financials | |
0.05M |
|
0.01M |
|
0.15M |
|
0.20M |
|
3.03M |
|
-- |
|
0.01M |
|
3.04M |
|
-2.84M |
|
-2.84M |
|
-2.84M |
|
0.70M |
|
| Cash Flow Statement Financials | |
-0.35M |
|
0.00M |
|
0.12M |
|
0.24M |
|
0.01M |
|
-0.22M |
|
0.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.02 |
|
-- |
|
-- |
|
-- |
|
-0.57 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-0.35M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
32.46% |
|
|
Return on Tangible Equity |
32.49% |
-470.24% |
|
32.49% |
|
-4.06 |
|
-0.50 |
|
-0.50 |
|